Clinical trials: Juvenile
Child Behavior Disorders
Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes
The goal of the current trial is to assess the feasibility of a newly developed prototype of a cell phone app called VillageWhere.
- Trial name
- VillageWhere (NCT02320903)
- Testing
- VillageWhere App
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Myopia, Myopia Progression
Myopia Control Spectacle Lens Cessation Study
To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- BIRCH (NCT05893979)
- Testing
- Spectacle Lenses
- Where
- 8 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Juvenile Idiopathic Arthritis
Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers
This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers.
- Trial name
- NCT01358383
- Testing
- naproxen, esomeprazole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myopia, Myopia Progression
Spectacle Lens Visual Acuity Assessments Study
This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- CEDAR (NCT05650190)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 6 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Juvenile Myopia, Myopia
CYPRESS Efficacy and Safety Study Extension
This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing…
- Trial name
- CYPRESS (NCT04947735)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 12 sites in United States, Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Rheumatoid Arthritis, Juvenile
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Juvenile Rheumatoid Arthritis (JRA).
- Trial name
- NCT00036374
- Testing
- Infliximab
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Systemic Juvenile Idiopathic Arthritis, Periodic Fever Syndrome
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody injection in Healthy Subjects.
- Trial name
- NCT05027373
- Testing
- SSGJ-613
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Juvenile Myopia
Myopia Assessment of Two Manufacturing Processes
Randomized, controlled, multisite, subject- and observer-masked, contralateral clinical trial of 6-month duration to compare two SightGlass Vision Diffusion Optics Technology (DOT) spectacle lens manufacturing processes in…
- Trial name
- MAPLE (NCT04126057)
- Testing
- SightGlass Vision DOT Spectacle Lenses
- Where
- 5 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Tay-Sachs Disease, Sandhoff Disease
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2
Primary Objectives: Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period…
- Trial name
- AMETHIST (NCT04221451)
- Testing
- venglustat GZ402671
- Where
- 23 sites in United States, Argentina and 11 more
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Myopia, Myopia Progression
Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness
The objective of the study is to measure the effect of Diffusion Optics Technology (DOT) spectacle lenses on the choroidal thickness and choroidal vascularity index compared to control lenses.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- ASH-2 (NCT05617794)
- Testing
- Diffusion Optics Technology (DOT) Pattern Spectacle Lens, Control Spectacle Lens
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Adolescent Idiopathic Scoliosis, Juvenile Idiopathic Scoliosis
Fusionless Treatment of Idiopathic Scoliosis With the SCOLI-TETHER System During The Growth Period
The goal of the study is to establish the safety and benefit of treatment of juvenile and adolescent idiopathic scoliosis (AIS) with the SCOLI-TETHER (MIScoli) System.
- Trial name
- FUTURE (NCT04992845)
- Testing
- Anterior Vertebral Body Tethering
- Where
- Canada
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Spino Modulation Inc.
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Juvenile Myopia
Control of Myopia Using Novel Spectacle Lens Designs
Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile…
- Trial name
- CYPRESS (NCT03623074)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 14 sites in United States, Canada
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia, Myopia Progression
Children's Viewing Behavior
The aim of this study is to investigate the area of the spectacle lens in which a subject is viewing through regardless of task being performed.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- NCT07229365
- Testing
- Novel spectacle lens design, Spectacle lens designs
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Juvenile Myopia, Myopia
Assessment of DOT Spectacles in Chinese Children Extension
This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing…
- Trial name
- CATHAY Ext (NCT07008001)
- Testing
- Novel spectacle lens design
- Where
- 5 sites in China
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia, Juvenile Myopia
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy.
- Conditions
- Myopia, Juvenile Myopia, Myopia Progression
- Trial name
- EUCALYPTUS (NCT06034327)
- Testing
- Single vision, impact-resistant spectacle lenses; Test Arm, Single vision, impact-resistant spectacle lenses; Control Arm
- Where
- 14 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Healthy Volunteers
A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants
The purpose of this study is to assess the PK comparability and compare safety and tolerability of DRL_AB administered via an auto injector (AI) or prefilled syringe (PFS) in healthy male participants.
- Trial name
- NCT07744828
- Testing
- DRL_AB
- Where
- 3 sites in New Zealand
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Juvenile Idiopathic Arthritis
Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers
To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in Chinese healthy adult volunteers
- Trial name
- NCT04337437
- Testing
- Genakumab
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Myopia
To Evaluate the Effectiveness of New Specially Designed Fitlens Soft Lens.
Myopia is a common disorder, affecting approximately one-third of the US population and over 90% of the population in some East Asian countries.
- Trial name
- NCT05433792
- Testing
- Myolens CN (Central-Near) soft contact lens, MiSight® soft contact lens
- Where
- Israel
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Fitlens Ltd.
Juvenile Myopia, Myopia
Assessment of DOT Spectacles in Chinese Children
This is a randomized, controlled, evaluator-blinded, multicenter, two-arm parallel group clinical trial to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses by comparing to single…
- Trial name
- CATHAY (NCT05562622)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 5 sites in China
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.